Purpura fulminans with Lemierre’s syndrome caused by *Gemella bergeri* and *Eikenella corrodens*: a case report

Toshinobu Yamagishi1*, Mayu Hikone1, Kazuhiro Sugiyama1, Takahiro Tanabe1, Yasuhiro Wada1, Michiko Furugaito2, Yuko Arai2, Yutaka Uzawa2, Ryo Mizushima2, Keisuke Kamada2, Yasutomo Itakura2, Shigekazu Iguchi2, Atsushi Yoshida2, Ken Kikuchi2 and Yuichi Hamabe1

**Abstract**

**Background:** *Gemella bergeri* is one of the nine species of the genus *Gemella* and is relatively difficult to identify. We herein describe the first case of septic shock due to a *Gemella bergeri* coinfection with *Eikenella corrodens*.

**Case presentation:** A 44-year-old Asian man with a medical history of IgG4-related ophthalmic disease who was prescribed corticosteroids (prednisolone) presented to our hospital with dyspnea. On arrival, he was in shock, and a purpuric eruption was noted on both legs. Contrast enhanced computed tomography showed fluid retention at the right maxillary sinus, left lung ground glass opacity, and bilateral lung irregular opacities without cavitation. Owing to suspected septic shock, fluid resuscitation and a high dose of vasopressors were started. In addition, meropenem, clindamycin, and vancomycin were administered. Repeat computed tomography confirmed left internal jugular and vertebral vein thrombosis. Following this, the patient was diagnosed with Lemierre’s syndrome. Furthermore, he went into shock again on day 6 of hospitalization. Additional soft tissue infections were suspected; therefore, bilateral below the knee amputations were performed for source control. Cultures of the exudates from skin lesions and histopathological samples did not identify any pathogens, and histopathological findings showed arterial thrombosis; therefore it was concluded that the second time shock was associated with purpura fulminans. Following this, his general status improved. He was transferred to another hospital for rehabilitation. The blood culture isolates were identified as *Gemella bergeri* and *Eikenella corrodens*. *Gemella bergeri* was identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry and confirmed by 16S rRNA gene sequencing later. The primary focus of the infection was thought to be in the right maxillary sinus, because the resolution of the fluid retention was confirmed by repeat computed tomography.

**Conclusions:** *Gemella bergeri* can be the causative pathogen of septic shock. If this pathogen cannot be identified manually or through commercial phenotypic methods, 16S rRNA gene sequencing should be considered.

**Keywords:** *Eikenella corrodens*, *Gemella bergeri*, Lemierre’s syndrome, MALDI-TOF MS, Purpura fulminans, Septic shock, 16S rRNA gene

---

* Correspondence: t_yamagishi0211@yahoo.co.jp
1Tertiary Emergency Medical Center, Tokyo Metropolitan Bokutoh Hospital, 4-23-15 Kotobashi, Sumida-ku, Tokyo 130-8575, Japan
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

*Gemella bergeri* is one of nine species (the others include *G. haemolysans, G. morbillorum, G. sanguinis, G. asaccharolytica, G. taiwanensis, G. parahaemolysans, G. cuniculi*, and *G. palanticanis*) belonging to the genus *Gemella* [1–3]. Because conventional biochemical methods may result in misidentification of *Gemella* as viridans group streptococci or other related organisms, they are relatively difficult to identify and considered uncommon organisms [4]. *G. bergeri* belongs to the normal flora of the oral cavity, and digestive and urinary tract, and was isolated for the first time by Collins et al. in 1998 [5]. Since then, it is gradually being recognized and so far, 13 cases have been reported [4–11] (Table 1). Except for one case associated with cardiogenic shock due to perforation of the mitral valve [4], there are no cases of septic shock due to *G. bergeri* infection.

We herein describe the first case of septic shock due to a *G. bergeri* coinfection with *E. corrodens*, which induced Lemierre’s syndrome and fulminant purpura.

Case presentation

A 44-year-old Asian man with a medical history of chronic sinusitis and IgG4-related ophthalmic disease who was prescribed 5 mg of oral corticosteroids (prednisolone) 2 years previously (initial dose was unknown) was transported to our hospital with dyspnea lasting for several hours. He smoked cigarettes 24 pack years but did not have a history of intravenous drug abuse, heavy drinking, or poor dental hygiene. He had not undergone dental procedures recently. On arrival, his Glasgow Coma Scale score was 11 (eye, 3; verbal, 2; motor, 6), body temperature 37.1 °C, his respiratory rate was 28/min, his blood pressure was 99/42 mmHg, and his heart rate was regular at 150 beats/min. His symptoms were not obvious because of his consciousness disturbance; his face had no skin erythema or swelling, and his neck induration could not be palpated. A purpuric eruption was covering both of legs. Transthoracic echocardiography showed a hypercontractile left ventricle without pericardial effusion, regurgitation of valves, and vegetations. Contrast enhanced computed tomography (CT) showed no obvious embolization at the bilateral pulmonary arteries, but revealed left lung ground glass opacity, and bilateral irregular lung opacities without cavitation. Fluid retention at the right maxillary sinus was also found. Laboratory test results were as follows: leukocyte count, 19,100 cells/μL; hemoglobin level, 15.7 g/dL; platelet count, 0.6 × 10^4 cells/μL; creatinine level, 4.1 mg/dL; total bilirubin level, 3.9 mg/dL; C-reactive protein level, 45.6 mg/dL; procalcitonin level, 44.7 ng/mL; β-D-glucan level, <6.0 pg/mL; a negative pneumococcal urinary antigen test; a negative *Legionella* urinary antigen test; prothrombin time international normalized ratio, 1.15; fibrin degradation products, 103 μg/mL; Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) scores, 7 points; and Sequential Organ Failure Assessment (SOFA) score, 15 points. Blood gas analysis results were as follows (10 L/minute O2 administered): pH, 7.174; PaCO₂, 32.7 mmHg; PaO₂, 177 mmHg; HCO₃⁻, 11.6 mmol/L; lactate 13.8 mmol/L; anion gap, 16.7 mmol/L. Owing to suspected bacterial pneumonia-induced septic shock and/or purpura fulminans, endotracheal intubation was performed, and fluid resuscitation was started immediately. After we obtained blood, sputum, and urine cultures, initial empiric antimicrobial drugs (meropenem, clindamycin, and vancomycin) were administered. Norepinephrine was initiated, titrated up to 25 μg/min. In addition, vasopressin 0.03 U/min, dobutamine 8 μg/kg/min, and hydrocortisone 200 mg/day were also added for continuous infusion. Because mean blood pressure could not be maintained at 50 mmHg despite adequate drip infusion and high dose vasopressors, venoarterial extracorporeal membrane oxygenation (VA-ECMO) was initiated due to refractory septic shock. Continuous hemodiafiltration (CHDF) was also introduced due to severe lactic acidosis, and recombinant thrombomodulin was administered for sepsis induced DIC. After the patient was admitted to the intensive care unit, his vital signs stabilized gradually. Both VA-ECMO and CHDF were tapered on day 2 post admission. Norepinephrine, vasopressin, and dobutamine were tapered on day 3, 4, and 5, respectively. Repeat contrast enhanced CT confirmed bilateral lung nodules, left internal jugular vein and vertebral vein thrombosis; following this Lemierre’s syndrome was diagnosed on day 6 (Figs 1 and 2). Although the primary focus of the infection was thought to be the right sinus, purpura worsened on both legs. He then went into shock again on day 6 (Fig. 3). Additional soft tissue infections were suspected; therefore, bilateral below the knee amputations were performed for source control. In addition to intravenous antibiotics, edoxaban (non-vitamin K antagonist oral anticoagulant) was initiated for left internal jugular and vertebral venous thrombosis. Following this, his vital signs improved without further systemic embolism. Cultures of the exudates from the skin lesions and histopathological samples did not identify any pathogens, and histopathological findings showed arteriole thrombosis, and therefore, it was thought that second time shock developed due to purpura fulminans in the context of the septic shock and DIC. A tracheotomy was performed on day 13, and intravenous antibiotics and edoxaban were discontinued on day 59 with disappearance of the neck thrombosis, and bilateral lung nodules and fluid retention at the right maxillary sinus as identified on repeat CT. Lastly, he was transferred to another hospital for rehabilitation on day 121.

Gram-negative coccobacilli and gram-positive cocci were yielded from two sets of blood culture bottles (BacT/ALERT, bioMérieux, Marcy l’Étoile, France), which were
Table 1: Cases of *Gemella bergeri* from 1998 to 2018

| Case | Age | Gender | Disease | Underlying disease | Antibiotics | Reason for changing antibiotics | Blood culture | How to diagnose | Operation | Outcome | Reference |
|------|-----|--------|---------|--------------------|-------------|----------------------------------|---------------|----------------|------------|---------|-----------|
| 1    | 42  | Male   | I E     | Mitral valve prolapse, periodontitis | NA          | NA                               | NA            | 16S rRNA gene sequence | Valve replacement | Admission | [5]       |
| 2    | NA  | NA     | I E     | NA                 | NA          | NA                               | NA            | 16S rRNA gene sequence | NA         | Survived | [5]       |
| 3    | NA  | NA     | I E     | NA                 | NA          | NA                               | NA            | 16S rRNA gene sequence | NA         | Survived | [5]       |
| 4*   | NA  | NA     | NA      | NA                 | NA          | NA                               | NA            | 16S rRNA gene sequence | NA         | Survived | [5]       |
| 5*   | NA  | NA     | NA      | NA                 | NA          | NA                               | NA            | 16S rRNA gene sequence | NA         | Survived | [5]       |
| 6*   | NA  | NA     | NA      | NA                 | NA          | NA                               | NA            | 16S rRNA gene sequence | NA         | Survived | [5]       |
| 7    | 32  | Male   | I E     | Bicuspid aortic valve | Ampicillin, gentamicin, rifampicin | No | Gram-positive cocci | 16S rRNA gene sequence | Ring abscess curettage, valve replacement | Survived | [6]       |
| 8    | 15  | Male   | I E     | Tetralogy of Fallot, pulmonary atresia | Vancomycin, gentamicin → ceftriaxone, rifampicin | Side effect | Gram-positive cocci | 16S rRNA gene sequence | NA | Survived | [7]       |
| 9    | 24  | Male   | I E     | Rheumatic heart disease | Ceftriaxone, gentamicin | No | Gram-positive cocci | Phenotypic method | Decompressive craniotomy | Death | [8]       |
| 10   | 50  | Male   | I E     | Bicuspid aortic valve | Amoxicillin-clavulanate, amikacin → ceftriaxone, gentamicin | Antibiogram results | Gemella bergeri | NA | No | Survived | [9]       |
| 11   | 37  | Male   | I E     | Tricuspid valve cleft | NA          | NA                               | Negative | Real-time PCR | Valve repair with vegetectomy | Survived | [10]      |
| 12   | 63  | Male   | I E     | Extensive dental procedure | Vancomycin, piperacillin-tazobactam, levofloxacin | No | Gram-positive cocci | Phenotypic method | No | Death | [4]       |
| 13   | 23  | Male   | I E     | Bicuspid aortic valve | Ceftriaxone, vancomycin → ampicillin, gentamicin | Antibiogram results | Gemella bergeri | NA | Mitral valve repair with vegetectomy, aortic valve replacement | Survived | [11]      |

1  E Infective endocarditis, NA Not applicable, PCR Polymerase chain reaction, RNA Ribonucleic acid; *These cases do not mention a clinical diagnosis and further clinical data
taken prior to antibiotic administration. The gram-negative coccobacilli were identified as *E. corrodens* by ID Test HN-20 Rapid (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) (profile: 5220000, %ID 99.9%) and susceptibility testing was determined by Etest (bioMérieux) in Mueller-Hinton agar plates (bioMérieux) (Table 2). These gram-positive cocci were catalase-negative and showed weak-beta hemolysis on 5% sheep blood agar (Nihon Becton-Dickinson, Tokyo, Japan), initially suspected as pyogenic streptococci, after 48 h of incubation under anaerobic and 5% CO₂ gas at 35 °C. This strain was not identified by the rapid ID 32 STREP system (profile 00002500000; low discrimination of *Erysipelothrix rhusiopathiae/Gemella hemolysans/Gemella morbillorum*, bioMérieux) but was identified as *G. morbillorum* by BD BBL Crystal GP (profile: 0500000100, %ID 98.5%, Becton-Dickinson, Sparks, MD, USA). It was identified as *G. bergeri* with a score value of 2.068 (species level) by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS, Autoflex II with MALDI Biotyper software ver 3.1; Bruker Daltonik GmbH, Bremen, Germany) and confirmed by 16S rRNA gene sequencing by the method described previously [12]. Phylogenetic analysis results are shown in Fig. 4. Susceptibility testing was then performed with MicroFAST Type 7 J Panels and MicroScan Walkaway-96 (Beckman Coulter, Brea, CA, USA). According to the Clinical and Laboratory Standards Institute (CLSI) document M45-A3 (Clinical and laboratory standards institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd edition, CLSI guideline M45. Clinical and laboratory standards institute, Wayne, PA. 2015), results of minimum inhibitory concentrations of various antimicrobials and interpretation of susceptibility testing are shown in Table 2. Based on these susceptibility results and negative results of additional blood cultures on day 6, antimicrobials started empirically were changed to ampicillin-sulbactam on day 10.

**Discussion**

This is the first case of septic shock due to a *G. bergeri* coinfection with *E. corrodens*. Furthermore, this coinfection induced Lemierre’s syndrome and purpura fulminans in the patient. This case highlighted two important clinical findings. First, although *G. bergeri* and *E. corrodens* are thought to be relatively harmless microorganisms, their coinfection might become severe. Second, MALDI-TOF MS and 16S rRNA gene sequencing can identify *G. bergeri*. *G. bergeri* was isolated for the first time by Collins et al. in 1998 [3]. Since then to our knowledge, thirteen cases have been reported [4–11] (Table 1). Three of these reports did not specifically mention a clinical

---

**Fig. 1** Imaging findings of a 44-year-old man who was diagnosed Lemierre’s syndrome. Contrast enhanced computed tomography on day 6 showed left internal jugular vein and vertebral vein thrombosis (arrow) (a. axial view, b. coronal view)

**Fig. 2** Echo scan investigation of the internal jugular vein. Echo scan of the internal jugular vein also showed the thrombosis (a. long axis view, b. short axis view)
diagnosis and were not described in detail. The remaining ten of them had endocarditis, eight of the ten patients showed good response to medical treatment and had a good clinical outcome, and two were fatal. In case report 9 (Table 1) the patient suffered intracerebral and subarachnoid hemorrhage secondary to rupture of a mycotic aneurysm [8], and in case 12, the patient expired due to cardiogenic shock owing to perforation of the mitral valve [4]. We obtained two sets of blood cultures twice during the treatment. G. bergeri and E. corrodens were detected in the first set of blood cultures. The second set of values on day 6 was negative, and no other pathogens were detected during the treatment. The Gemella and Eikenella were the only pathogens that were identified during the treatment; thus, these two were thought to be the causative agents associated with sepsis in our case. The coinfection of E. corrodens with other pathogens is common. The outcomes are apparently not severe, but sometimes become severe with certain pathogens [13]. Another study reported that both coaggregation and growth stimulation occur between E. corrodens and Streptococcus [14]. Although the virulence factors of Gemella and E. corrodens are not well understood, we recognize now that they might cause septic shock.

Early identification of the source of the infection, or the causative pathogen, and appropriate antimicrobial administration are crucial in patients with sepsis and septic shock [15]. Gemella spp. tend to be misidentified due to the tendency to easily decolorize in Gram staining, and commercial biochemical tests are still incapable of identifying all of the strains accurately. A molecular method such as 16S rRNA gene sequence analysis is a useful tool for accurate identification [1, 5–7]. In our case, at first, we misidentified G. bergeri as beta-hemolytic streptococcus spp. and changed the empirical therapy to ampicillin-sulbactam as a definitive therapy. Fortunately, the susceptibility of G. bergeri was good, and the patient was therefore treated adequately. However, although intravenous ceftriaxone, gentamicin and oral rifampicin are effective antibiotics [4, 6–9, 11] (Table 1), one study showed evidence of resistance to drugs such as penicillin [16], erythromycin [17], levofloxacin and aminoglycosides [1] for Gemella. Therefore, obtaining an accurate diagnosis of Gemella using a 16S rRNA gene sequence analysis should be considered if the pathogens are not identified by Gram staining or commercial biochemical tests. In addition, susceptibility testing should be performed for appropriate antimicrobial therapy.

Lemierre’s syndrome is diagnosed based on following findings: 1) primary infection in the oropharynx, 2) bacteremia demonstrated by at least one positive blood culture, 3) evidence of thrombophlebitis of the internal jugular vein, and 4) metastatic infections at one or more distant sites [18]. The overall mortality in the past 5 years based on a recent systematic review of 137 cases from 2016 was found to be 2%, and the majority of causative pathogens were Fusobacterium; Gemella were not detected [19]. Only two cases

Table 2 Susceptibility testing for Eikenella corrodens and Gemella bergeri

| Pathogens and antimicrobial agents | MIC (mg/L) and interpretation of susceptibility |
|-----------------------------------|-----------------------------------------------|
| **E. corrodens**                  |                                               |
| Amoxicillin-clavulanic acid       | 0.25/0.125 (S)                                |
| Cefotaxime                        | 0.06 (S)                                      |
| Imipenem                          | 0.38 (S)                                      |
| Clindamycin                       | 24 (NA)                                       |
| **G. bergeri**                    |                                               |
| Benzylpenicillin                  | ≤0.03 (S)                                     |
| Cefotaxime                        | ≤0.125 (S)                                    |
| Ceftriaxone                       | ≤0.125 (S)                                    |
| Meropenem                         | ≤0.125 (S)                                    |
| Vancomycin                        | 1 (S)                                         |
| Erythromycin                      | ≤0.125 (S)                                    |
| Levofloxacin                      | ≤0.25 (S)                                     |
| Clindamycin                       | ≤0.125 (S)                                    |

MIC: Minimum inhibitory concentration, NA: Not available in CLSI M45-A3 documents, S: Susceptible
in their study that discussed infections with *Klebsiella pneumoniae* and *Streptococcus anginosus* involved fatal outcomes [19]. Anticoagulation for the internal jugular vein and ligation of the occluded vein are still controversial issues. However, if the patients failed to respond to antibiotics, they required anticoagulant treatment and/or surgical treatment to prevent further septic embolism or for resolution of septic processes [19, 20]. In our case, internal vein surgery was not needed. Evidence of further systemic septic embolism was not found, mainly due to the administration of appropriate broad-spectrum empiric antimicrobial therapy and adjunctive therapy such as anticoagulant treatment. The duration of antibiotic therapy is reported to be from 10 days to 8 weeks [19], but the reason is not explained adequately. We expect that the optimal duration will be studied further in future studies.

### Conclusion
Compromised patients such as our patient are susceptible to infection. *G. bergeri* can be a causative pathogen of septic shock. If a pathogen cannot be identified by conventional biochemical methods, MALDI-TOF MS or 16S rRNA gene sequencing should be considered.

### Abbreviations
CHDF: Continuous hemodiafiltration; CLSI: Clinical and laboratory standards institute; CT: Computed tomography; DIC: Disseminated intravascular coagulation; MALDI-TOF MS: Matrix-assisted laser desorption ionization-time of flight mass spectrometry; VA-ECMO: Venoarterial extracorporeal membrane oxygenation

### Acknowledgments
The authors would like to thank Editage (https://www.editage.jp) for their English language editing.

### Authors’ contributions
TY, MH, KS, and TT were attending physicians, and YW was the attending orthopedic surgeon for the patient and collected medical data of the patient. MF, YA, YU, RM, and KK1 participated in bibliographic research. SI, AY, and KK2 were involved in microbiological analysis of gene sequence analysis and susceptibility testing. TY and KK2 drafted the manuscript. All authors were involved in critical review of the manuscript. YH revised the article. TY edited the manuscript for important intellectual and scientific content, served as the principal author, and edited the revised version. All authors read and approved the final draft.

### Ethics approval and consent to participate
The institutional review board of Tokyo Metropolitan Bokutoh Hospital approved this case report. The authors also obtained an informed consent from the patient and his relatives.

### Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

### Competing interests
The authors declare that they have no competing interests.

### Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Author details
1Tertiary Emergency Medical Center, Tokyo Metropolitan Bokutoh Hospital, 4-23-15 Kotobashi, Sumida-ku, Tokyo 130-8575, Japan. 2Department of Infectious Diseases, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
1. Hikone M, Sakamoto N, Ota M, Washino T, Kobayashi KI, Iwabuchi S, et al. The first case report of infective endocarditis caused by Gemella taiwanensis. J Infect Chemother. 2017;23:567–71.
2. Hoyles L, Foster G, Falsen E, Collins MD. Characterization of a Gemella-like organism isolated from an abscess of a rabbit: description of Gemella cunicula sp.nov. Int J Syst Evol Microbiol. 2000;50:2037–41.
3. Collins MD, Rodríguez Jovita M, Foster G, Sjödén B, Falsen E. Characterization of a Gemella-like organism isolated from the oral cavity of a dog: description of Gemella palatianan sp.nov. Int J Syst Bacteriol. 1999;49:1532–6.
4. Ukudeeva A, Hawkins HK, Ahmad M, Deeprasertkul P, Rincon L, Kimbrel BK, et al. Second fatal case of infective endocarditis caused by Gemella bergeri. Int J Biomed. 2017;7:63–6.
5. Collins MD, Huston RA, Falsen E, Sjödén B, Facklam RR. Gemella bergeriae sp. nov., isolated from human clinical specimens. J Clin Microbiol. 1998;36:1290–3.
6. Elsayed S, Zhang K. Gemella bergeri endocarditis diagnosed by sequencing of rRNA genes in heart valve tissue. J Clin Microbiol. 2004;42:4897–900.
7. Logan LK, Zheng X, Shulman ST. Gemella bergeri endocarditis in a boy. Pediatr Infect Dis J. 2008;27:184–6.
8. Hussain K, Abubaker J, Al Deesi ZO, Ahmed R. Unreported neurological complications of Gemella bergeri infective endocarditis. BMJ Case Rep 2014. pii:bcr2014204405. https://doi.org/10.1136/bcr-2014-204405.
9. Vigilio E, Chieco PA. Sixth case of infective endocarditis caused by Gemella bergeri. Braz J Infect Dis. 2014;18:467.
10. Pachitari O, Watt G, Pussadhamma B. First case of tricuspid valve endocarditis caused by Gemella bergeri. Case Rep Med. 2015;2015:1–3.
11. Zaidi SJ, Husayni T, Collins MA. Gemella bergeri infective endocarditis: a case report and brief review of literature. Cardiol Young. 2018;28:762–4.
12. Tohya M, Arai S, Tomida J, Kawamura Y, Katsumi M, Ushimizu M, et al. Defining the taxonomic status of Streptococcus suis serotype 33: the proposal for Streptococcus ruminantium sp. nov. Int J Syst Evol Microbiol. 2017;67:3660–5.
13. Paul K, Patel SS. Eikenella corrodens infections in children and adolescents: case reports and review of the literature. Clin Infect Dis. 2001;33:54–61.
14. Young KA, Allaker RP, Hardie JM, Whitley RA. Interactions between Eikenella corrodens and 'Streptococcus milleri-group' organisms: possible mechanisms of pathogenicity in mixed infections. Antonie Van Leeuwenhoek. 1996;69:371–3.
15. Rhodes A, Evans LE, Aghazzari W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304–77.
16. Vasishtha S, Isenberg HD, Sood SK. Gemella morbillorum as a cause of septic shock. Clin Infect Dis. 1996;22:1084–6.
17. Zolezzi PC, Cepeiro PG, Ruiz J, Laplana LM, Calvo CR, Gómez-Lus R. Molecular epidemiology of macrolide and tetracycline resistances in commensal Gemella sp. isolates. Antimicrob Agents Chemother. 2007;51:1487–90.
18. Sinave CP, Hardy GJ, Fardy PW. The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection. Medicine. 1989;68:85–94.
19. Johansson KM, Bodtger U. Lemierre’s syndrome: current perspectives on diagnosis and management. Infect Drug Resist. 2016;9:221–7.
20. Murray M, Stevens T, Herford A, Roberts J. Lemierre syndrome: two cases requiring surgical intervention. J Oral Maxillofac Surg. 2013;71:310–5.